Change of CEO planned at Johnson & Johnson

20 August 2021

US healthcare giant Johnson & Johnson (NYSE: JNJ) revealed yesterday that long-serving Alex Gorsky, who has held the posts of chairman and chief executive since 2012, will serve as executive chairman of the group.

The CEO role will transition to Joaquin Duato, who is currently vice chairman of the company's executive committee, effective January 3, 2022. Mr Duato will also be appointed as a member of the company's board of directors.

Mr Gorsky said in a statement it was the right time to make the switch for both the company and him personally as he focuses more on family due to "family health reasons."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK